Metastasis is the leading cause of death in patients with osteosarcoma, the most common pediatric bone malignancy. We conducted a multistage genome-wide association study of osteosarcoma metastasis at diagnosis in 935 osteosarcoma patients to determine whether germline genetic variation contributes to risk of metastasis. We identified an SNP, rs7034162, in NFIB significantly associated with metastasis in European osteosarcoma cases, as well as in cases of African and Brazilian ancestry (meta-analysis of all cases: P = 1.2 × 10 −9
iNtRODUctiON
Metastasis to distant secondary sites is the cause of death for the majority of cancer patients; a defining feature of osteo sarcoma is its high rate of metastasis. Osteosarcoma is the most common primary malignant bone tumor, with a main incidence peak in adolescence during the pubertal growth spurt and a second, smaller peak in the seventh and eighth decades of life (1) (2) (3) . Epidemiologic data suggest that growth may contribute to osteosarcoma etiology, and several studies have found common genetic variants associated with risk of osteosarcoma (3) (4) (5) (6) . However, the disease course for patients with osteosarcoma is variable, and the pathogenesis and prognostic factors that contribute to this variability remain poorly understood.
Patients presenting with metastatic osteosarcoma have a very poor prognosis, with 5year overall survival rates rang ing from 11% to 29% (7) (8) (9) (10) . Approximately 10% to 25% of patients with osteosarcoma have metastases at the time of diagnosis, and up to 90% of these metastasize to the lungs (11) (12) (13) (14) . Several factors have been inconsistently proposed to be associated with primary metastasis, including older age, low socioeconomic status, larger tumor size, and tumor loca tion (7, 9, 10, 12, 13) . However, the largest international col laborative study of osteosarcoma to date found that none of the clinical or demographic factors evaluated were associated with metastasis; they found that the presence of metastasis at diagnosis increased the risk of a subsequent metastasis 5fold (14) .
To our knowledge, there have been no studies evaluating the role of genetic variation in osteosarcoma metastasis, and there may be an underlying genetic component contribut ing to the risk of metastasis. A connection between germline genetic variation and susceptibility to metastasis has been recently reported in other cancers (15) (16) (17) ; however, we are unaware of any studies evaluating the association between germline genetic variation and metastasis in pediatric can cers. Here, we assembled clinical outcome data on 935 oste osarcoma cases from our recent genomewide association study (GWAS; ref. www.aacrjournals.org determine if common germline genetic variation is associated with risk of metastasis at diagnosis of osteosarcoma. We fur ther used in vitro studies to functionally characterize a novel metastasisassociated locus.
ResUlts

Variants at 9p24.1 Associated with Metastasis at Diagnosis
The discovery analysis included 541 cases of European ancestry that passed qualitycontrol metrics and had data on the presence of confirmed metastases at diagnosis (Sup plementary Table S1 ). Metastatic disease was present in 23% of patients with osteosarcoma at diagnosis and was associated with a significantly reduced overall survival [P = 1.9 × 10 −19 , HR 4.3, 95% confidence intervals (CI), 3.13-5.91; Supplementary Table S2 ]. Age at diagnosis, gender, tumor subtypes, and tumor location were not significantly different in the patients with metastases at diagnosis compared with patients without metastases at diagnosis (Supplementary  Table S2 ).
An adjusted logistic regression model with logadditive effects identified one locus at 9p24.1 associated with metas tasis that approached genomewide significance in our dis covery analysis (Supplementary Table S3 ; Supplementary  Fig. S1 ). Specifically, six linked intronic SNPs in the nuclear factor I/B gene (NFIB) on chromosome 9p24.1 were sig nificantly associated with an increased risk of metastasis (top SNP rs2890982: P = 4.4 × 10 −7 ; OR, 2.69; 95% CI, 1.83-3.94; Table 1 and Fig. 1A) . Evaluation of associations with metas tasis at diagnosis for the top SNP by inheritance model suggested no departure from the logadditive model (Sup  plementary Table S4 ).
We examined variants at 9p24.1 in 85 osteosarcoma cases using targeted genotyping of this region (replication set 1; Supplementary Table S1 ). The top 100 SNPs from the dis covery set were also evaluated in an additional 141 independ ent cases with GWAS data (replication set 2; Supplementary  Table S1 ). A fixedeffect metaanalysis was applied to combine the results of each replication set (226 total unique cases) and the discovery set (541 unique cases). In the metaanalysis, the 9p24.1 locus marked by SNP rs2890982 was strongly associ ated with metastasis at diagnosis (P = 4.9 × 10 −8 ; OR, 2.60; 95% CI, 1.87-3.62; Table 1 ).
To further evaluate this locus, we imputed SNPs across a 1Mb region centered on the index SNP on 9p24.1. Meta analyses of the imputed SNPs from both replication sets and the discovery set showed a similar increased risk of metastasis associated with rs7034162 (P = 3.3 × 10 −8 ; OR, 2.62; 95% CI, 1.86-3.68; r 2 = 0.8 with rs2890982; Table 1 and Fig. 1B; Supplementary Table S4 ). Only the imputed index SNP (rs7034162) additionally showed an association with an increased risk of metastasis in cases of African (N = 61) and Brazilian (N = 107) ancestry with GWAS data (Supplementary Table S1 ); in a metaanalysis combining all cases (European discovery/replication, African, and Bra zilian ancestry cases; N = 935), the rs7034162 association with metastasis gained significance (P = 1.2 × 10 −9 ; OR, 2.43; 95% CI, 1.83-3.24; Table 1 and Fig. 1C; Supplemen  tary Table S5 ).
We additionally evaluated associations for the top SNPs in the European discoverystage cases compared with the European controls from our previous GWAS [N = 2,703; ref. 5; minor allele frequencies (MAF) for the controls are shown in Supplementary Table S6 ]. For the top SNP, rs7034162, the minor allele (A) was significantly associated with an ). Con versely, there was a borderline statistically significant inverse association for the minor allele of rs7034162 comparing the cases without metastasis with the controls (OR, 0.77; 95% CI, 0.60-0.99, P = 0.039).
Furthermore, the rs7034162 risk allele (A) was significantly associated with worse overall survival in the European cases (discovery stage; N = 522) and in all cases (European discovery, African, and Brazilian ancestry cases; N = 684) with survival data, with a perallele HR of 1.34 (95% CI, 1.01-1.77, logrank P = 0.044) and 1.45 (95% CI, 1.16-1.81, logrank P = 3.3 × 10 −4 ; Kaplan-Meier survival curve shown in Fig. 1D ), respectively. When we restricted our survival analyses to only the cases without metastasis at diagnosis, including all cases from the discovery stage, replication 3, and replication 4 (N = 494), the rs7034162 risk allele (A) was associated with worse overall sur vival, with a perallele HR of 1.29 (95% CI, 0.92-1.80, logrank P = 0.124), although not statistically significant.
Both rs2890982 (g.14181653 C>T) and rs7034162 (g.14190287 T>A) are located in intron 4 of the NFIB gene (Fig. 1 ) with the most statistically significant SNP, which is labeled and shown in purple. Allelic P values generated by SNPTEST using score method (two-sided). Physical locations of the SNPs are based on NCBI human genome build 36, and gene annotation was based on the NCBI RefSeq genes from the UCSC Genome Browser. A, European discovery set. B, meta-analyzed European discovery and replication sets (imputed). C, meta-analyzed European discovery/replication sets, plus African and Brazilian ancestry cases (imputed). D, Kaplan-Meier curve of cumulative (cum) survival for patients with osteosarcoma by the rs7034162 genotype. 
Decreased NFIB Expression Is Associated with the Risk Allele of rs7034162
We performed expression quantitative trait locus (eQTL)-based analyses using publicly available expression and geno typing data on 17 osteosarcoma cell lines and 29 tumors (20) . We evaluated whether topranking SNPs were associated with expression of NFIB or other neighboring proteinencoding genes. The risk allele (A) of rs7034162 was significantly asso ciated with a decrease in NFIB expression in osteosarcoma cell lines (N = 17, P = 0.0059) and osteosarcoma tumors (N = 29, P = 0.0211; Fig. 2 ; Supplementary Fig. S3 ). There was no association between rs7034162 genotypes and expression of other nearby proteinencoding genes (FREM1, ZDHHC21, and MPDZ; Fig. 2 ; Supplementary Fig. S4 ).
NFIB Expression Levels Are Associated with Migration and Growth of Osteosarcoma Cells
The ability of tumor cells to invade and migrate is an important marker of metastatic potential. Therefore, to evaluate the possible involvement of NFIB in osteosarcoma metastatic potential, we analyzed the invasion and migra tion capacity of three human osteosarcoma cell lines (U2OS, HOS, and OSA) with different expression levels of NFIB. U2OS and HOS cells carry the homozygous nonrisk allele (rs7034162: TT), whereas OSA cells carry the homozygous risk allele (rs7034162: AA). U2OS and HOS had significantly higher NFIB expression levels and higher NFIB protein levels than OSA cells ( Fig. 3A ; Supplementary Figs. S3 and S5A). A Matrigel Transwell invasion and migration assay demon strated that the invasion and migration rates were inversely correlated with NFIB expression levels in the osteosarcoma cell lines (Fig. 3A and B) . siRNA molecules against NFIB were used to deplete NFIB; all three osteosarcoma cell lines showed reduced NFIB mRNA and protein levels compared with control (siNEG)treated cells ( Fig. 3A ; Supplementary  Fig. S5B ). After knockdown of NFIB, there was an increase of invasion and migration in all three osteosarcoma cells compared with the control (Fig. 3B ). U2OS and HOS cells, with high endogenous NFIB expression, had a statistically significant increase in invasion and migration after NFIB ) . B, forty-eight hours after NFIB suppression, cells were evaluated for migratory potential. Cells that invaded through the Matrigelcoated membrane inserts were stained with crystal violet and air-dried, and bright field images were taken (inset photographs depict staining intensity differences). To quantify cell invasion/migration, the inserts were treated with 200 μL of methanol and the absorbance measured in triplicate at 560 nm. Invading cells are depicted relative to controltreated U2OS cells. Results of at least three experiments in triplicate are expressed as mean ± SD. The invasion and migration rate of each cell line was inversely correlated with NFIB expression levels. knockdown (P = 0.009 and 0.015, respectively). In the OSA cell line, with low endogenous NFIB expression, there was a small nonsignificant increase in invasion and migration after NFIB suppression (P = 0.151; Fig. 3A and B) . These find ings were confirmed in woundhealing cell migration assays and filamentous actin staining assays; there was increased migration of osteosarcoma cells treated with siRNA against NFIB compared with the control (Fig. 4A-C) . Staining for filamentous actin showed increased podia formation in all three osteosarcoma cell lines after NFIB suppression (shown for U2OS in Fig. 4C ), typical of migrating cells.
We blindly replicated our findings using a softagar colony formation assay in HOS, OSA, and U2OS cells. Overexpres sion of NFIB resulted in a significant reduction in colony formation in HOS (P < 0.0001) and OSA (P < 0.0001) cells (Fig. 4D) . The U2OS cells did not show a significant change in colony formation with NFIB overexpression. This was expected because NFIB expression is already high in U2OS ( Fig. 3A; Supplementary Figs. S3 and 5A ). In addition, overexpression of NFIB resulted in a significant reduction of wound healing in HOS and OSA cells (data not shown).
NFIB is a transcription factor that regulates insulinlike growth factor binding protein 5 (IGFBP5) expression in human osteoblasts, and IGFBP5 has been shown to inhibit tumor growth and metastasis of human osteosarcoma cells (21, 22) . Therefore, we evaluated if there was a relationship between NFIB and IGFBP5 expression levels in osteosarcoma cell lines and tumors. We found a statistically significant direct correlation between NFIB and IGFBP5 expression levels (P = 1.17 × 10 −5 ; Supplementary Fig. S6 ). The AA risk allele of rs7034162 was significantly associated with lower IGFBP5 and NFIB expression in osteosarcoma cell lines and tumors ( Supplementary Fig. S3 ). The U2OS and HOS cells, both car rying the homozygous nonrisk allele (rs7034162: TT), had higher NFIB and IGFBP5 expression levels than the OSA cells (carrying the homozygous risk allele, rs7034162: AA; Supple mentary Figs. S3 and S7). In addition, NFIB siRNA suppres sion led to the downregulation of IGFBP5 in HOS and U2OS cells (Supplementary Fig. S7 ).
Mice with Primary Osteosarcomas and Metastases Harbor Inactivating Transposon Insertions in Nfib
A connection between Nfib and osteosarcoma was also iden tified in a sleeping beauty (SB) transposon mutagenesis system in mice (23 ; Fig. 5A ). We evaluated tumor tissues from these mice and found a reduced expression of both Nfib (P = 0.087) and Igfbp5 (P = 0.048) in tumors with inactivating transposon insertions compared with tumors lacking insertions in Nfib (Fig. 5B and C) . We used IHC stain ing for NFIB in sections of mouse tumor and adjacent bone to further evaluate tissuespecific changes in NFIB expression. There was a significantly reduced labeling intensity in the osteosarcoma cells with an Nfib insertion compared with the adjacent normal osteoblasts (P = 0.0018; Fig. 5D and E). There was no NFIB labeling of any osteoclast cells. These mouse data confirm our human cell line findings and further suggest that a decreased expression of NFIB, leading to downregulation of IGFBP5, is important for metastatic ability.
DiscUssiON
This first multistage GWAS of osteosarcoma metastasis identified a common SNP, rs7034162, in NFIB at 9p24.1 associated with metastasis at diagnosis of osteosarcoma. We replicated the strong association identified in 541 European patients in an additional 394 patients from four case studies, including patients of European, African, and Brazilian ances try. Our data showed that the risk SNP was associated with a decrease in NFIB expression, and, importantly, there was no association with expression of other nearby proteinencoding genes. Therefore, we focused on characterizing the role of NFIB in osteosarcoma metastatic potential.
NFIB is a member of the NFI gene family, which are site specific DNAbinding proteins, also known as CAAT box tran scription factors; they function in both viral DNA replication and the regulation of genes expressed in almost every organ and tissue (24) . NFIBmediated transcriptional activation or repression of specific gene promoters varies depending on cell type and gene promoter, resulting in the modulation of the expression of more than 100 diverse tissuespecific genes (24) . NFIB gene rearrangements and fusions with either HMGA2 or MYB have been reported in lipoma, salivary gland, breast, and head and neck tumors (25) (26) (27) (28) . Changes in NFIB expres sion have been associated with specific miRNAs, and NFIB has been reported as a tumor suppressor in some cancers and an oncogene in other cancers (29) (30) (31) (32) (33) . This implication in both the inhibition and promotion of tumor development and progression in different cancers corroborates the diverse and distinct roles of NFIB in specific tissues and cancer sites. NFIB has not been previously implicated in osteosarcoma etiology or osteosarcoma metastasis. Here, we have shown that lowered NFIB leads to increased osteosarcoma cell line migration, proliferation, and colony formation, which sug gests its involvement in osteosarcoma metastasis. The mouse SB transposon mutagenesis screen independently identified Nfib with close to genomewide significance to be a tumor suppressor gene (23), and we further showed that osteosar comas in mice with Nfib insertions had significantly reduced NFIB compared with the adjacent normal osteoblasts.
Because NFIB had previously been shown to directly regu late IGFBP5 expression in human osteoblasts (34), the relevant cell type, we hypothesized that the association of NFIB with osteosarcoma metastases may be mediated through IGFBP5. Interestingly, IGFBP5 has been previously shown to inhibit tumor growth and metastasis of human osteosarcoma cells (21, 22) , growth of mouse osteosarcoma cells (35) , and migra tion of human breast cancer cells (36) . IGFBP5 is the most abundant IGFBP stored in bone, and it has been shown to regulate osteoblast proliferation and differentiation (37, 38) . Thus, NFIB may modulate osteoblast proliferation and dif ferentiation through the modulation of IGFBP5 expression. IGFBP5 can also both inhibit and enhance insulinlike growth factors (IGF), the critical regulators of bone metabolism (38) . The IGF1-IGF1R axis is important for metastasis and migra tion and has been associated with osteosarcoma risk and sur vival (20, (39) (40) (41) (42) (43) (44) (45) (46) . We found a direct correlation between NFIB and IGFBP5 expression in osteosarcoma cell lines and tumors, and the rs7034162 risk allele of NFIB was also associated with reduced IGFBP5 expression. We hypothesize that the NFIB risk allele leads to lowered expression of NFIB and NFIBmediated lower expression of IGFPB5, which results in less IGFBP5 mediated inhibition of IGF1 (47) . This may then lead to an IGF1-IGF1R axis-mediated increase in proliferation, survival, and metastasis of osteosarcoma cells (Supplementary Fig. S8) .
Metastatic osteosarcoma at diagnosis signifies a poor prog nosis, and, in our study, 23% of patients had metastasis at diagnosis. There are few factors that have been consistently associated with risk of metastasis (14) . We have identified a con nection between germline genetics and osteosarcoma metasta sis at diagnosis and further showed that the risk SNP likely has a role in osteosarcoma metastasis through an effect on NFIB expression levels. Our data suggest that germline genetic varia tion at rs7034162 in the NFIB gene contributes to susceptibility to metastasis at diagnosis in patients with osteosarcoma.
MethODs
Study Populations
A summary of the participating studies is given in Supplementary  Table S1 . Five hundred fortyone osteosarcoma cases of European ancestry were included in the discovery set from our previous GWAS, as described (5) . Three hundred thirtythree unique osteosarcoma cases for replication of the discovery set findings were from the Genetic Epidemiology of Osteosarcoma study (COG AEPI05N2), the registry component of the Children's Oncology Group (COG), through the University of Minnesota, as previously described (6); the International Sarcoma Kindred Study, Melbourne, VIC (Australia); the Therapeutically Applicable Research to Generate Effective Treat ments (TARGET) dataset (48) ; and from the Instituto de Oncologia Pediátrica GRAACC/UNIFESP and Universidade Federal de Sao Paulo (Brazil). TARGET data were used only for the analysis of the NFIB gene region. Cases from COG AEPI05N2 were restricted to those of European ancestry, as in the discovery set (5) . Cases of African ances try were identified in four studies in the discovery set (Supplementary Table S1) in our previous GWAS ancestry evaluation using a STRUC TURE analysis and principal component analysis (PCA; ref. 5) .
Patients were diagnosed in the individual hospitals and were prospectively followed up as part of their osteosarcoma treatment. Study centers provided data on patient and clinical variables that were harmonized between the studies, including age at diagnosis, gender, survival, relapse, followup, tumor subtype, tumor location, and the presence of histologically confirmed metastatic or nonmeta static disease at diagnosis. All tumors were histologically confirmed. Not all patients had all variable data. In this study, we focused on the presence or absence of metastatic disease at diagnosis and did not exclude cases that experienced a later relapse. Participating subjects provided informed consent; studies were conducted in accordance with the Declaration of Helsinki and approved by local Institutional Review Boards.
Genotyping
Germline genomic DNA was extracted from either blood or buccal cells drawn from osteosarcoma case series using standard methods. Genotyping of all cases with GWAS data was conducted using the Illumina OmniExpress SNP microarray. Qualitycontrol filtering www.aacrjournals.org was performed as previously described (5). We included autosomal SNPs with a MAF of ≥5% in the discovery stage, SNPs with a ≥90% completion rate, and SNPs with no evidence of deviation from the Hardy-Weinberg proportion (P > 1 × 10 −7 ). SNPs were excluded if they had abnormal heterozygosity values of <20% or >31%, expected duplicates, and abnormal Xchromosome heterozygosity. There were 29 duplicated cases with concordance rates of 99.96%. Genotypes for all subject pairs were also computed for close relationships (first and second degree) using the GLU qc.ibds module (49) with an IBD0 threshold of 0.70; no firstdegree relatives were identified in the cases scanned. SNPs (447,040) passed qualitycontrol metrics for the 541 discovery set cases for final analysis. Only cases of >80% European ancestry were included in the discovery GWAS and the replication COG AEPI05N2 analysis based on STRUCTURE analysis (50) and PCA (51), as previously determined (5) . PCA (52) results for indi viduals in the discovery stage are shown in Supplementary Fig. S9 ; there were no significant differences between populations (P > 0.1).
The top NFIB SNPs associated with metastasis at diagnosis from the discovery set were genotyped using Taqman assays in the Inter national Sarcoma Kindred Study cases, and data from TARGET for osteosarcoma cases were used to examine NFIB SNPs (replication set 1). The top 100 SNPs associated with metastasis at diagnosis were chosen for followup in the COG AEPI05N2 cases (replication set 2) and in cases of African and Brazilian ancestry with GWAS data.
We validated the top imputed SNP, rs7034162, to confirm the imputed genotype using TaqMan assays in 89 cases with GWAS data from the discovery stage (16% of the total 541 cases). TaqMan assay (Life Technologies) validation and SNP genotyping were performed at the Cancer Genomics Research Facility. The imputation genotype error rate was 1.12% (1 case had the wrong genotype).
Genomic Annotation
For all imputed and genotyped SNPs with a P value of less than 1 × 10 −5 (N = 75) in the NFIB locus, genomic annotation of SNP markers was conducted using the ENCODE (19) tool HaploReg (53), Regu lomeDB (54), and LDlink (55).
eQTL Analysis
We performed eQTLbased analyses using publicly available geno type and expression data from 17 osteosarcoma cell lines (GSE36004) and 29 tumors (GSE33383; ref. 20) . U2OS, HOS, and SJAS1 (OSA) osteosarcoma cell lines were included as part of the 17 osteosarcoma cell lines with data and are highlighted in Supplementary Figs. S3 and S4.
Cell Lines
The human osteosarcoma cell lines U2OS, HOS, and SJAS1 (OSA) were obtained from the ATCC for our in vitro studies (March 2014). Cell lines were tested for authentication (February 2015) with a panel of short tandem repeats (STR) using the Identifiler Kit (Life Technologies) and compared with the ATCC STR Profile Databases. Osteosarcoma cells were maintained at 37°C in a humidified atmos phere with 5% CO 2 in RPMI1640 (Cellgro) supplemented with 10% fetal calf serum (FCS; Gibco; Life Technologies).
PB/SBCAGGOIGFPPGKPURO-based transposon overexpres sion vectors were generated using the LR Clonase Gateway cloning system (Invitrogen) with cDNAs in Entry vectors with the previ ously described PB/SBCAGDESTGFPPGKPURO, following the manufacturer's instructions (56). NFIB was purchased from Open Biosystems in Gateway ready pENTR221 vector. NFIB and Luciferase overexpression cell lines were generated by electroporation using 2 μg PB7 transposase and 2 μg transposon plasmid with the NEON trans fection system (Invitrogen), following the manufacturer's protocol. After 2 days, cells were selected with 1 μg/mL puromycin to obtain stable cell lines.
RNA Interference
A mix of three siRNA molecules against NFIB and a negative con trol siRNA (ONTARGETplus, D0018100120; Thermo Scientific) were purchased from Dharmacon. Subconfluent osteo sarcoma cells were transfected in 6well plates using Lipofectamine RNAiMAX Transfection Reagent according to the manufacturer's instructions (Life Technologies). Efficacy of the transfection protocol was tested using siGLO (D0016300220) according to the manufacturer's instruc tions (Thermo Scientific). NFIB sequences used were (i) AGGAUACU CUGAAGAACUAUU, (ii) GCAAAAGACCCAAAACUAUUU, and (iii) ACUAGAAGAAGCCUGAAAUU.
RNA Isolation and Quantitative Real-Time PCR for NFIB and IGFBP5
Total RNA was isolated using the RNeasy Mini Kit according to the manufacturer's instructions (Qiagen). cDNA was synthesized from total RNA using the HighCapacity cDNA Reverse Transcrip tion Kit, as described by the manufacturer's protocol (Applied Biosys tems; Life Technologies). Quantitative realtime PCR was performed using TaqMan Gene Expression Master Mix (Life Technologies). The expression of NFIB (Hs01029175_m1) and IGFBP5 (Hs00181213_ m1) was normalized to the level of HPRT1 (4326321E) in the same sample, resulting in a ΔCt from which the 2 −ΔCt value was derived and compared with controltreated U2OS cells. Results of at least three experiments in triplicate are expressed as mean ± SD.
Cell Invasion/Migration by Transwell Matrigel Assay
Subconfluent osteosarcoma cells were infected with the indicated siRNAs or controls. Fortyeight hours after infection, osteosarcoma cells were seeded in RPMI onto the basement membrane matrix (Corning BioCoat Matrigel Invasion Chambers). The Transwell was placed in a 24well plate that contained 500 μL RPMI1640 with 10% FCS as chemo attractant. After 24 hours, the noninvading cells and Matrigel matrix were gently removed with a cotton swab. Invasive cells located on the lower side of the chamber were stained with crystal violet, airdried, and photographed. To quantify cell invasion/ migration, the inserts were treated with 200 μL methanol, and the absorbance was measured in triplicate at 560 nm using the GloMax Multi Detection System (Promega). Results of at least three experi ments in triplicate are expressed as mean ± SD.
Wound-Healing Cell Migration Assay
Subconfluent osteosarcoma cells were infected with the indicated siRNAs or controls. Wounds were made on the monolayers using a pipette tip 48 hours after infection. Bright field images were taken at time 0 and 16, 24, and/or 30 hours. After the final image (at 16, 24, or 30 hours), the plates were washed, cells fixed with methanol, and stained with Crystal Violet (C008 Hardy Diagnostics).
Filamentous Actin Staining
Cells were seeded on coverslips and treated for 48 hours with siRNA as indicated. Six hours after wounds were made, cells were fixed with 4% paraformaldehyde in PBS for 10 minutes and blocked with 0.1% Triton X100 and 1% BSA in PBS for 20 minutes. This was followed by incubation with Alexa Fluor 488 Phalloidin (Life Technologies) in 0.1% Triton X100 and 1% BSA in PBS for 20 minutes to stain filamen tous actin. Finally, cells were mounted with ProLong Diamond Anti fade Mountant with DAPI (Life Technologies). The LSM 700 confocal laser scanning microscope (Zeiss) was used for analysis.
Soft-Agar Colony-Formation Assay
Cells (1 × 10 4 ) were seeded into soft agar in single wells of 6well plates and allowed to incubate for 2 to 3 weeks. The resultant colo nies were then stained with 0.5% crystal violet in buffered formalin for
Research. Colonies were quantified using ImageJ software using a standard colony quantification macro.
Osteosarcoma SB Screen
The results of the complete SB screen have been previously pub lished (23) . Briefly, mice were generated to target SB mutagenesis only in osteoblast cells in wildtype or Trp53-deficient mice. Genes found to be significantly mutated by transposon mutagenesis were then identified. gCIS analysis of T2/Onc insertion sites was performed using genecentric software, as previously described (57) .
RNA was extracted from SBmutagenized tumors using the RNA miniprep kit (Invitrogen) and reverse transcribed into cDNA using the Superscript III reverse transcriptase kit (Invitrogen), following the manufacturer's instructions. Eleven primary tumors with insertions in Nfib and 11 primary tumors without insertions in Nfib were ana lyzed. Quantitative RTPCR was performed using FastStart Universal SYBR Green Master (Rox) mix (Roche) using an Eppendorf Realplex2 Mastercycler EP Gradient S. Primer sequences were as follows: NFIB forward: TTCCCCAAGATTGAGCACTT, NFIB reverse: GGATAGCTT GCGTCGGAAA; IGFBP5 forward GTACCTGCCCAACTGTGAC, IGFBP5 reverse GCTTCATTCCGTACTTGTCCA; and normalized to GAPDH, forward GTGTTCCTACCCCCAATGTGT and reverse GAGACAACCTGGTCCTCAGTGT.
Western Blot and IHC Staining
Tissues were fixed in 10% buffered formalin and embedded in paraffin blocks. Sections were cut at 5μm thickness and rehydrated through a series of graded ethanols. Slides underwent antigen retrieval by boiling for 30 minutes in antigen unmasking solution (Vector Laboratories Inc.). Endogenous peroxidases were quenched with 3% hydrogen peroxide solution for 20 minutes. For antibody staining, 10% goat serum in 1× PBST was used for blocking and antibody incubations. Primary NFIB antibody was used at 1:250 (HPA003956; SigmaAldrich). Following a series of washes, slides were incubated with biotinylated goat antirabbit secondary antibody (1:250; Vector Laboratories Inc.). Slides were washed, incubated with the vectastain ABC Kit (Vector Laboratories Inc.) for 30 minutes at room tem perature, washed again, and stained using a peroxidase substrate kit DAB (Vector Laboratories Inc.). Finally, slides were counterstained with hematoxylin, dehydrated, cleared with xylene, and mounted with Permount (Fisher Scientific). Immunoblot analysis was performed on wholecell lysates harvested using RIPA buffer (SigmaAldrich) supplemented with phosphatase inhibitors and protease inhibitors (SigmaAldrich). Lysates were separated by SDSPAGE, transferred to a polyvinylidene difluoride membrane (Invitrogen), incubated in 5% BSA in trisbuffered saline and tween (TBST) to block nonspecific binding, and probed with appropriate antibodies. Proteins were detected on a LICOR Odyssey Fc instrument using a chemiluminescent horseradish peroxidase substrate (Advansta). NFIB antibody used for IHC above was also utilized for immunoblot analysis.
Staining intensity within 16 tumors and adjacent, normal osteo blasts (internal positive control) was assessed by the semiquantitative Hscore (58), which was determined by summing the products of the percent of cells with weak (1 × %), moderate (2 × %), and strong (3 × %) nuclear staining, with a maximum possible score of 300.
Statistical Analyses
Cases with confirmed metastasis at diagnosis were compared with cases without metastasis at diagnosis. In the discovery and replica tion stages, risk of metastasis at diagnosis was estimated using logistic regression to calculate the OR and 95% CIs per copy of the minor allele assuming a multiplicative (logadditive) genetic model with 1 degree of freedom. Logistic regression models were adjusted for study center; age and gender were not significantly associated with metastasis, and thus were removed from the model. Because there were no significant eigenvectors from the PCA of osteosarcoma cases (P > 0.1), they were not included in the model. The estimated inflation factor, λ, of the test statistic for the discovery set was 0.9107 ( Supplementary Fig. S10 ). Logistic regression models for the evalu ation of SNP associations comparing the European discovery stage cases with the European controls from our previous GWAS (5) were adjusted for gender and the two significant eigenvectors from the PCA of cases and controls. We had 91.9% power to detect an OR of 2.60 with 122 cases with metastasis and 419 cases without metastasis at an alpha of 0.05 and allele frequency of 10%.
An inversevariance fixedeffect metaanalysis was applied to com bine the results of the discovery set and replication sets. Between stages heterogeneity was quantified with I 2 (59). We did not observe significant heterogeneity for the top reported SNPs: rs2890982, EUR metaanalysis of discovery and replication sets: I 2 = 0%, P het = 0.39; rs7034162, all ancestry metaanalysis of discovery and replication sets: I 2 = 17.9%, P het = 0.30. We imputed additional SNPs within 1 Mb on either side of the implicated SNPs using IMPUTE2 software and the reference data from both the 1000 Genomes project (March 2012 release; ref. 18) and the DCEG Imputation Reference Set version 1 (60) . SNPTEST was used to analyze the posterior SNP dosages from IMPUTE2, adjusting for study center, as described above (61) .
A timetoevent analysis for overall survival was assessed in the osteosarcoma cases with these data using Cox proportional hazards regression to estimate HRs and 95% CIs adjusted for study center, ancestry, gender, and age. Not all cases had followup and survival data; only 522 European ancestry cases included in the discovery stage, 57 African ancestry cases in replication 3, and 105 Brazilian ancestry cases in replication 4. Overall survival time was estimated as the time from the date of diagnosis until the date of death or the last known alive date; patients were censored at the last date to be alive or if lost to followup. Kaplan-Meier survival curves were created, and P values were estimated with a Mantel-Cox logrank test.
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